Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 3Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Tumor-Agnostic 1Breast 1

Conditions

Neuroendocrine Tumors 1Intestinal Neuroendocrine Tumor 1

Interventions

lutetium Lu 177 dotatate 41Everolimus 38Magnetic Resonance Spectroscopy 18Temozolomide 17lanreotide 16gallium Ga 68 dotatate 15Octreotide 14pembrolizumab 13Nivolumab 13Capecitabine 12cabozantinib 11177Lu-octreotide, DOTA(0)-Tyr(3)- 11surufatinib 9pasireotide 9Sunitinib 9Specimen Handling 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Lutetium-177 8Carboplatin 8amino-acid, glucose, and electrolyte solution 6Ipilimumab 6Ga(III)-DOTATOC 6Fluorodeoxyglucose F18 6Etoposide 6Cisplatin 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5copper dotatate CU-64 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Data Collection × NET × Clear all
NCT06876532 2025-11-18

LUTIBI

Institut Claudius Regaud

Phase NA Recruiting
150 enrolled
EndocrineNET

Intestinal Neuroendocrine Tumor

NCT05017662 2025-09-04

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

Ariceum Therapeutics GmbH

Phase NA Completed
20 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡